NeuroNEXT

Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-Hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, McNeill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J

Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial

PubMed: PMID:35088051

Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O’Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ; NeuroNEXT NN103 BeatMG Study Team.

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study

PubMed: PMID: 34857535

Lowenhaupt, Stephanie; Malloy, Angela

Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network

PubMed: PMC8340117

Carillo N, Malicdan MC, Leoyklang P, Shrader JA, Joe G, Slota C, Perreault J, Heiss JD, Class B, Liu CY, Bradley K, Jodarski C, Ciccone C, Driscoll C, Parks R, Van Wart S, Bayman L, Coffey CS, Quintana M, Berry SM, Huizing M, and Gahl WA

Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 Study

PubMed: PMID: 34257421

Ken Sakaie, Janel K Fedler, Jon W Yankey, Kunio Nakamura, Josef Debbins, Mark J Lowe, Paolo Raska, Robert J Fox

Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis

PubMed: PMC8138298

Naismith RT, Bernel RA, Coffey CS, Goodman AD, Fedler JK, Chase M, Klawiter EC, Nakamura K, Narayanan S, Goebel C, Yankey JW, Klingner EA, Fox RJ.

Effects of Ibudilast on MRI measures in the Phase 2 SPRINT-MS Study

PubMed: PMC7905793

Goodman AD, Fedler JK, Yankey J, Klingner EA, Ecklund DJ, Goebel CV, Bernel RA, Chase M, Coffey CS, Klawiter EC, Naismith RT, Fox RJ on behalf of the SPRINT-MS Investigators.

Response to Ibudilast treatment according to progressive multiple sclerosis disease phenotype

PubMed: PMC7818089

Robert A Bermel, Janel K Fedler, Peter Kaiser, Cindy Novalis, Jeff Schneebaum, Elizabeth A Klingner, Dawn Williams, Jon W Yankey, Dixie J Ecklund, Marianne Chase, Robert T Naismith, Eric C Klawiter, Andrew D Goodman, Christopher S Coffey and Robert J Fox

Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis

PubMed: 33054533

Merit Cudkowicz, MD, MSc; Marianne K. Chase, BA; Christopher S. Coffey, PhD; Dixie J. Ecklund, RN, MSN, MBA;
Brenda J. Thornell, BA; Codrin Lungu, MD; Katy Mahoney, BS; Laurie Gutmann, MD; JeremyM. Shefner,MD, PhD;
Kevin J. Staley, MD; Michael Bosch, RN; Eric Foster, PhD; Jeffrey D. Long, PhD; Emine O. Bayman, PhD;
James Torner, PhD; Jon Yankey, MS; Richard Peters, BS; Trevis Huff, BSE; Robin A. Conwit, MD;
and the NeuroNEXT Clinical Study Sites

Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials

PubMed: PMC7483960

Michael J. Brownstein, Neal G. Simon, Jeffrey D. Long, Jon Yankey, Hilda T. Maibach, Merit Cudkowicz, Christopher Coffey, Robin A. Conwit, Codrin Lungu, Karen E. Anderson, Steven M. Hersch, Dixie J. Ecklund, Eve M. Damiano, Debra E. Itzkowitz, Shifang Lu, Marianne K. Chase, Jeremy M. Shefner, Andrew McGarry, Brenda Thornell, Catherine Gladden, Michele Costigan, Padraig O’Suilleabhain, Frederick J. Marshall, Amy M. Chesire, Paul Deritis, Jamie L. Adams, Peter Hedera, Kelly Lowen, H. Diana Rosas, Amie L. Hiller, Joseph Quinn, Kellie Keith, Andrew P. Duker, Christina Gruenwald, Angela Molloy, Cara Jacob, Stewart Factor, Elaine Sperin, Danny Bega, Zsazsa R. Brown, Lauren C. Seeberger, Victor W. Sung, Melanie Benge, Sandra K. Kostyk, Allison M. Daley, Susan Perlman, Valerie Suski, Patricia Conlon, Matthew J. Barrett, Stephanie Lowenhaupt, Mark Quigg, Joel S. Perlmutter, Brenton A. Wright, Elaine Most, Guy J. Schwartz, Jessica Lamb, Rosalind S. Chuang, Carlos Singer, Karen Marder, Joyce A. Moran, John R. Singleton, Meghan Zorn, Paola V. Wall, Richard M. Dubinsky, Carolyn Gray and Carolyn Drazinic

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

PubMed: PMC7696926